AI Summary & Key Takeaways
AI InsightMedian progression-free survival (PFS) was 12.3 months (95% confidence interval [CI], 9.4-15.1), and the median overall survival (OS) was 24.3 months (95% CI, 15.8-32.8).
📌 3 Key Takeaways
Abstract
Objective: Malignant mesothelioma is a rare and aggressive cancer. We aim to report our experience of stage 1 and 2 malign pleural mesothelioma (MPM) and investigate the prognostic factors. Methods: We retrospectively reviewed 37 patients with clinical stage 1 and 2 MPM in our center and examined radiological findings, demographic characteristics, treatment modalities, survival, and recurrence. Results: Eighteen of the 37 patients were male, and the mean age of the patients was 59.0 ± 11.2 years. Thirty patients had stage 1 MPM, and 7 patients had stage 2. Seven patients underwent surgery, and 30 patients received induction chemotherapy. Median progression-free survival (PFS) was 12.3 months (95% confidence interval [CI], 9.4-15.1), and the median overall survival (OS) was 24.3 months (95% CI, 15.8-32.8). In multivariate analysis, while gender and surgery had a statistically significant effect on PFS (p=0.01, p=0.01, respectively), both gender and surgery did not significantly affect OS (p=0.15, p=0.08, respectively). Local recurrence occurred in 28 patients, and 7 patients were presented with local recurrence and distant metastasis. Conclusion: In our study, where the majority of patients were stage 1 and 2, the effect of the surgery was significant.